Public Employees Retirement System of Ohio Takes $13.94 Million Position in DexCom, Inc. $DXCM

Public Employees Retirement System of Ohio purchased a new stake in shares of DexCom, Inc. (NASDAQ:DXCM) during the 2nd quarter, Holdings Channel reports. The fund purchased 207,036 shares of the medical device company’s stock, valued at approximately $13,944,000.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. MassMutual Private Wealth & Trust FSB grew its stake in shares of DexCom by 15.4% during the second quarter. MassMutual Private Wealth & Trust FSB now owns 1,147 shares of the medical device company’s stock worth $77,000 after buying an additional 153 shares during the last quarter. V Square Quantitative Management LLC boosted its holdings in shares of DexCom by 1.8% during the 1st quarter. V Square Quantitative Management LLC now owns 9,618 shares of the medical device company’s stock valued at $604,000 after acquiring an additional 172 shares in the last quarter. Essex Financial Services Inc. boosted its holdings in shares of DexCom by 5.7% during the 1st quarter. Essex Financial Services Inc. now owns 3,256 shares of the medical device company’s stock valued at $204,000 after acquiring an additional 175 shares in the last quarter. Keel Point LLC grew its position in DexCom by 3.1% during the 4th quarter. Keel Point LLC now owns 6,473 shares of the medical device company’s stock worth $430,000 after acquiring an additional 193 shares during the last quarter. Finally, Integrated Wealth Concepts LLC grew its position in DexCom by 6.3% during the 1st quarter. Integrated Wealth Concepts LLC now owns 3,329 shares of the medical device company’s stock worth $227,000 after acquiring an additional 196 shares during the last quarter. Institutional investors own 97.75% of the company’s stock.

Insider Activity at DexCom

In other DexCom news, EVP Michael Jon Brown sold 1,700 shares of the stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $75.55, for a total transaction of $128,435.00. Following the completion of the sale, the executive vice president owned 106,353 shares of the company’s stock, valued at approximately $8,034,969.15. This represents a 1.57% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kevin R. Sayer sold 26,756 shares of the firm’s stock in a transaction that occurred on Monday, July 20th. The stock was sold at an average price of $76.32, for a total transaction of $2,042,017.92. Following the transaction, the insider owned 328,970 shares of the company’s stock, valued at approximately $25,106,990.40. The trade was a 7.52% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 75,600 shares of company stock valued at $5,673,342 over the last ninety days. Insiders own 0.28% of the company’s stock.

DexCom Price Performance

Shares of NASDAQ:DXCM opened at $90.82 on Monday. The firm has a market cap of $34.27 billion, a P/E ratio of 35.90, a P/E/G ratio of 1.53 and a beta of 1.41. The company has a quick ratio of 1.43, a current ratio of 1.73 and a debt-to-equity ratio of 0.47. DexCom, Inc. has a 12-month low of $54.11 and a 12-month high of $92.59. The business has a fifty day simple moving average of $79.21 and a 200 day simple moving average of $71.61.

DexCom (NASDAQ:DXCM) last announced its earnings results on Thursday, July 30th. The medical device company reported $0.70 EPS for the quarter, topping the consensus estimate of $0.61 by $0.09. DexCom had a return on equity of 35.94% and a net margin of 20.12%.The firm had revenue of $1.31 billion for the quarter, compared to the consensus estimate of $1.29 billion. During the same period in the previous year, the business earned $0.48 EPS. The business’s quarterly revenue was up 13.1% compared to the same quarter last year. Analysts predict that DexCom, Inc. will post 2.64 earnings per share for the current year.

Analysts Set New Price Targets

DXCM has been the subject of a number of recent research reports. Mizuho upped their target price on DexCom from $90.00 to $95.00 and gave the stock an “outperform” rating in a report on Friday, July 31st. Robert W. Baird set a $105.00 price target on DexCom in a report on Friday, July 31st. JPMorgan Chase & Co. upped their price objective on DexCom from $65.00 to $82.00 and gave the company a “neutral” rating in a research note on Friday, July 31st. William Blair upgraded shares of DexCom to a “strong-buy” rating in a report on Friday, May 15th. Finally, Barclays reiterated an “underweight” rating and set a $64.00 target price (down from $67.00) on shares of DexCom in a research report on Monday, May 18th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $88.71.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.